1. Diagnosis of histologically or cytologically proven prostate 
2. Patient must have either measurable or non measurable 
3. Received prior castration by orchiectomy and/or Luteinizing 
4. Life expectancy 2 months 
5. Eastern Cooperative Oncology Group (ECOG) performance 
6. Age 18 years 
1. Previous treatment with mitoxantrone 
7. Active secondary cancer including prior malignancy from which 
8. Known brain or leptomeningeal involvement 
11. Other concurrent serious illness or medical conditions 
12. Inadequate organ function as evidenced by the following 
15. Uncontrolled diabetes mellitus 
18. Participation in another clinical trial with any investigational drug 
19. Concurrent or planned treatment with strong inhibitors of 
1.1 STUDY FLOWCHART 
11.2 PROCEDURE FOR WITHDRAWAL OF PATIENTS FROM STUDY FOLLOW UP 
15.4 USE AND COMPLETION OF CASE REPORT FORMS (CRFS) AND ADDITIONAL 
3 LIST OF ABBREVIATIONS 
4 INTRODUCTION AND RATIONALE 
4.1 BACKGROUND 
4.2 XRP6258 
4.2.1 XRP6258 Preclinical activity 
4.2.2 Clinical Activity of XRP6258: Available Results 
4.2.3 Clinical PK of XRP6258: Preliminary Available Results 
4.3 RATIONALE 
4.3.1 Rationale for Dose Selection 
4.3.2 Rationale for Pharmacokinetics 
5 STUDY OBJECTIVES 
5.1 PRIMARY 
5.2  To compare efficacy between the two treatment arms: 
6 STUDY DESIGN 
6.1 DESCRIPTION OF THE PROTOCOL 
6.2 DURATION OF STUDY PARTICIPATION 
6.3 STUDY COMMITTEES 
7 SELECTION OF PATIENTS 
7.1 NUMBER OF PATIENTS PLANNED 
7.2 INCLUSION CRITERIA 
7.3 EXCLUSION CRITERIA 
8 TREATMENTS 
8.1 INVESTIGATIONAL PRODUCT (IP) 
8.2 PACKAGING AND LABELING 
8.3 STORAGE CONDITIONS 
8.3.1 Mitoxantrone 
8.3.2 Prednisone 
8.4 PREPARATION OF INVESTIGATIONAL PRODUCT 
8.5 DOSING REGIMEN 
8.5.1 Dose Modifications 
8.5.1.1 Myelosuppression 
8.5.1.2 Allergy (Anaphylactic and Hypersensitivity reactions) 
8.5.1.3 Nausea/Vomiting 
8.5.1.4 Diarrhea 
8.5.1.5 Stomatitis 
8.5.1.6 Peripheral neuropathy 
8.5.1.7 Liver toxicity 
8.5.1.8 Other Toxic Effects 
8.5.1.9 Mitoxantrone induced cardiac toxicity 
8.6 COMPENSATION FOR LACK OF BLINDING 
8.7 METHOD OF ASSIGNING PATIENTS TO TREATMENT GROUP 
8.8 RESPONSIBILITIES 
8.9 RETRIEVAL AND/OR DESTRUCTION OF TREATMENTS 
8.10 CONCOMITANT TREATMENT 
8.11 TREATMENT ACCOUNTABILITY AND COMPLIANCE 
9 ASSESSMENT OF INVESTIGATIONAL PRODUCT 
9.1 EFFICACY 
9.1.1.1 Overall Survival 
9.1.2 Secondary criteria 
9.1.2.1 Prostate Specific Antigen 
9.1.2.2 Tumor Lesion Assessment 
9.1.2.3 Progression Free Survival 
9.1.2.4 Pain 
9.2 SAFETY 
9.3 PHARMACOKINETICS 
9.3.1 Sampling time 
9.3.2 PK handling procedure 
9.3.3 Bioanalytical method 
10 PATIENT SAFETY 
10.1 SAFETY ENDPOINTS ASSESSED IN THIS TRIAL 
10.2 ADVERSE EVENTS MONITORING 
10.3 DEFINITIONS OF ADVERSE EVENT (AE) AND SERIOUS ADVERSE EVENT (SAE) 
10.4 OBLIGATION OF THE INVESTIGATOR REGARDING SAFETY REPORTING 
10.5 OBLIGATIONS OF THE SPONSOR 
11 HANDLING OF PATIENT TEMPORARY OR DEFINITIVE 
11.1 DEFINITIVE TREATMENT DISCONTINUATION WITH INVESTIGATIONAL 
11.1.1 List of criteria for definitive treatment discontinuation 
11.1.2 Handling of patients after definitive treatment discontinuation 
11.2 PROCEDURE FOR WITHDRAWAL OF PATIENTS FROM STUDY FOLLOW UP 
12 STUDY PROCEDURES 
12.1 VISIT SCHEDULE 
12.1.1.1 Day 28 to Randomization/initial dose of study drug 
12.1.2 Study Days 
12.1.3 End of treatment / withdrawal 
12.1.4 Post treatment follow up (survival or long term follow up) 
12.2 DEFINITION OF SOURCE DATA 
13 STATISTICAL CONSIDERATIONS 
13.1 SAMPLE SIZE DETERMINATION 
13.2 ANALYSIS VARIABLES 
13.2.1 Demographic and baseline characteristics 
13.2.2 Efficacy variables 
13.2.2.1 Primary efficacy variable 
13.2.2.2 Secondary efficacy variables 
13.2.3 Safety variables 
13.2.4 Pharmacokinetic variables 
13.3 ANALYSIS POPULATIONS 
13.3.1 Efficacy populations 
13.3.1.2 Clinical Trial Protocol deviations 
13.3.2 Safety population 
13.3.3 Other analysis population 
13.3.4 Disposition of patients 
13.4 STATISTICAL METHODS 
13.4.1 Demographic and baseline characteristics 
13.4.1.2 Previous medications 
13.4.2 Extent of study treatment exposure and compliance 
13.4.3 Analysis of efficacy variables 
13.4.3.1 Analysis of primary efficacy variable 
13.4.3.2 Analysis of secondary efficacy variables 
13.4.4 Analysis of safety data 
13.4.4.1 Adverse Events 
13.4.4.2 Laboratory safety data 
13.4.5 Analyses of pharmacokinetic variables 
13.4.5.1 Sample size determination for Pharmacokinetics 
13.4.5.2 Population PK model 
13.4.5.3 Statistical on PK parameters 
13.5 DATA HANDLING CONVENTIONS 
13.6 INTERIM ANALYSIS 
14 ETHICAL AND REGULATORY STANDARDS 
14.1 ETHICAL PRINCIPLES 
14.2 LAWS AND REGULATIONS 
14.3 INFORMED CONSENT 
14.4 INSTITUTIONAL REVIEW BOARD/INDEPENDENT ETHICS COMMITTEE (IRB/IEC) 
15 STUDY MONITORING 
15.1 RESPONSIBILITIES OF THE INVESTIGATOR (S) 
15.2 RESPONSIBILITIES OF THE SPONSOR 
15.3 SOURCE DOCUMENT REQUIREMENTS 
15.4 USE AND COMPLETION OF CASE REPORT FORMS (CRFS) AND ADDITIONAL 
15.5 USE OF COMPUTERIZED SYSTEMS 
16 ADMINISTRATIVE RULES 
16.1 CURRICULUM VITAE 
16.2 RECORD RETENTION IN STUDY SITE(S) 
17 CONFIDENTIALITY 
18 PROPERTY RIGHTS 
19 DATA PROTECTION 
20 INSURANCE COMPENSATION 
21 SPONSOR AUDITS AND INSPECTIONS BY REGULATORY 
22 PREMATURE DISCONTINUATION OF THE STUDY OR 
22.1 DECIDED BY THE SPONSOR IN THE FOLLOWING CASES: 
22.2 DECIDED BY THE INVESTIGATOR 
23 CLINICAL TRIAL RESULTS 
24 PUBLICATIONS AND COMMUNICATIONS 
25 CLINICAL TRIAL PROTOCOL AMENDMENTS 
26 BIBLIOGRAPHIC REFERENCES 
2. Collection/Handling/Processing of Samples 
3. PACKAGING AND SHIPMENT OF SAMPLES 
4. SHIPMENT CONTACT NAME AND ADDRESSES 
1 POINT 
4 POINTS 
